<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002560</url>
  </required_header>
  <id_info>
    <org_study_id>94-018</org_study_id>
    <secondary_id>CDR0000063466</secondary_id>
    <secondary_id>NCI-V94-0416</secondary_id>
    <nct_id>NCT00002560</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma</brief_title>
  <official_title>PHASE II TRIAL OF MONOCLONAL ANTIBODY 3F8 AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) FOR NEUROBLASTOMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver&#xD;
      tumor-killing substances to them without harming normal cells. Combining colony-stimulating&#xD;
      factors, such as sargramostim, with monoclonal antibodies may be an effective treatment for&#xD;
      advanced neuroblastoma.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody 3F8 plus&#xD;
      sargramostim in treating patients who have advanced neuroblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Define the antitumor effects of monoclonal antibody 3F8/sargramostim (3F8/GM-CSF) in&#xD;
           patients with advanced neuroblastoma.&#xD;
&#xD;
        -  Assess the biological effects of 3F8/GM-CSF in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive monoclonal antibody 3F8 IV over 1.5 hours on days 0-4 and 7-11 and&#xD;
      sargramostim (GM-CSF) IV over 2 hours on days -5 to 11. Treatment is repeated every 4 weeks&#xD;
      for up to 4 courses in the absence of progressive disease, HAMA response, or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 11-40 patients will be accrued for this study over 4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1994</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Neuroblastoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>monoclonal antibody 3F8</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Neuroblastoma diagnosed by INSS criteria, i.e., either:&#xD;
&#xD;
               -  Histologic proof of disease OR&#xD;
&#xD;
               -  Tumor clumps in bone marrow plus elevated catecholamine levels&#xD;
&#xD;
          -  Relapsed disease with poor long-term prognosis as indicated by at least one of the&#xD;
             following:&#xD;
&#xD;
               -  N-myc amplification in tumor cells&#xD;
&#xD;
               -  Diploid chromosomal content in tumor cells&#xD;
&#xD;
               -  Distant skeletal metastases&#xD;
&#xD;
               -  Unresectable primary tumor crossing the midline&#xD;
&#xD;
               -  Bone marrow with greater than 10% tumor cells&#xD;
&#xD;
          -  Documentation of measurable progressive disease or biopsy- proven stable disease at&#xD;
             least 4 weeks after prior systemic therapy required&#xD;
&#xD;
          -  No rapidly progressive disease&#xD;
&#xD;
          -  Poor risk neuroblastoma (but without measurable disease) not eligible for other&#xD;
             neuroblastoma protocols&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  2 to 21&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Greater than 8 weeks&#xD;
&#xD;
        Hematologic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  No grade 3/4 toxicity&#xD;
&#xD;
          -  LDH no greater than 1.5 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No grade 3/4 toxicity&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No grade 3/4 toxicity&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No grade 3/4 toxicity&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No grade 3/4 neurologic, gastrointestinal, or other organ toxicity except grade 3&#xD;
             hearing deficit&#xD;
&#xD;
          -  No active life threatening infections&#xD;
&#xD;
          -  No human antimouse antibody (HAMA) greater than 1,000 ELISA units/mL&#xD;
&#xD;
          -  No allergy to mouse proteins&#xD;
&#xD;
          -  No pain requiring opiates&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Standard chemotherapy to which disease is resistant or myeloablative therapy followed&#xD;
             by disease recurrence required&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian H. Kushner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 27, 2013</last_update_submitted>
  <last_update_submitted_qc>June 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2013</last_update_posted>
  <keyword>recurrent neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

